{"entity":{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","aka":[],"tldr":"Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.","summary":"Avenzo Therapeutics, based in San Diego, in-licenses Chinese oncology assets for Western development, including the Nectin-4 by TROP2 bispecific antibody-drug conjugate AVZO-103 and a CDK2 inhibitor. Its pipeline comprises AVZO-103, AVZO-021, the CDK2 inhibitor, and AVZO-1418, an EGFR by HER3 ADC. OnCo links it to Nectin-4 and TROP2 as targets and to the bispecific ADC technology. Whether a company that licenses rather than discovers can differentiate in a crowded bispecific ADC field is the open question. The bispecific ADC page carries the wider context.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.avenzotx.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":["nectin4","trop2"],"drugs":["avzo-021","avzo-023"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05867251","nct07193511","nct07038343"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.avenzotx.com","investors":[],"funding":[]},"route":"/companies/avenzo/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"},{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/"}],"trial":[{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/"},{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/"},{"id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/"},{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/"}],"technology":[{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"company":[{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/"}]}}